Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bahrain begins child screening programme:

This article was originally published in Clinica

Executive Summary

Bahrain is to begin screening 6,000 children for diseases, including sickle cell anaemia, beta thalassaemia and glucose-6 phosphate dehydrogenase (G6PD) deficiency in March 2003. The project is funded by the Bahrain society for hereditary diseases (BSHD) to the tune of BD20,000 ($53,200) and has the backing of the ministries of health and education. BSHD has already begun purchasing the equipment required for the screening programme. It will take the total number of children screened in Bahrain over the past five years to 30,000. Bahrain's current infant screening programme has helped lower the number of children born with hereditary diseases from 2.1% in 1986 to 0.9% today, said Dr Al Arrayed of the Salmaniya Medical Complex genetics department, in Manama.

You may also be interested in...



Sanofi Skates To Where The Puck Is With Immunology

The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.

Pipeline Watch: Five Approvals And 23 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel